Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
AChR Myasthenia Gravis: full-pipeline trial registry
2 of 2 indexed AChR Myasthenia Gravis trials are currently recruiting.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
AChR Myasthenia Gravis: 2 US clinical trials tracked, 2 recruiting.
AChR Myasthenia Gravis is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is COUR Pharmaceutical Development Company, running 1 of these trials.
Enrollment posture brief
Registry condition achr-myasthenia-gravis
OPEN 2 | RECR 100% | LATE 1 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
AChR Myasthenia Gravis lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for AChR Myasthenia Gravis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
AChR Myasthenia Gravis is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
COUR Pharmaceutical Development Company
NCT06106672
Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod
University of Colorado, Denver
NCT06860633
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on AChR Myasthenia Gravis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on AChR Myasthenia Gravis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this AChR Myasthenia Gravis page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 AChR Myasthenia Gravis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- COUR Pharmaceutical Development Company sponsors the most AChR Myasthenia Gravis trials on record, review their full trial history before evaluating a specific study. See COUR Pharmaceutical Development Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This AChR Myasthenia Gravis condition card totals 2 registered trials; most-linked intervention CNP-106; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.